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Introduction: Post-hospital syndrome (PHS) is defined as a period of vulne-
rability during the first 30 days after a patient is discharged from hospital, in 
which multiple factors come into play. Hyponatremia is the most frequent 
hydroelectrolytic disorder in hospitalized patients and may be related to the 
appearance of PHS. Objective: The objective is to estimate the prevalence of 
PHS that is assessed as the rate of readmissions in the first 30 days after dis-
charge, in patients with hyponatremia. Material and Methods: It is a 
descriptive observational study of patients with hyponatremia who were 
discharged from 1 September 2010 to 2 February 2020 at the Internal 
Medicine Service of the Hospital University of San Juan (Alicante, Spain). 
Results: Of the 25 included patients, 5 (20%) were readmitted within a month 
of discharge, after a mean of 11.4 days (standard deviation [SD] 5.1). The 
overall mortality of the study was 20% (n = 5), with one case of death in the 
first 30 days post-hospitalization (4%). In 12 patients (48%) the origin of the 
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hyponatremia was undetermined. The most frequently recorded etiology for 
the condition was pharmacological (n = 7, 28%), and there was pronounced 
variability in its clinical and laboratory study. The most widely used correc-
tive measure was drug withdrawal, in 16 patients (64%). Water intake restric-
tion was the most common treatment after discharge (5 patients, 20%), fol-
lowed by urea (2 patients, 8%), while tolvaptan was not used. Conclusion: 
Hyponatremia may be the cause of PHS, which could increase the rate of ear-
ly readmission. Hyponatremia is an underdiagnosed and undertreated entity, 
so it is necessary to apply an appropriate system to optimize its management 
and, in future studies, to assess its impact on PHS. 
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The term “post-hospitalization syndrome” (PHS), first coined by Krumkohlz, is 
used to describe the set of symptoms that can appear in the first 30 days follow-
ing hospital discharge, a period marked by greater vulnerability and a higher risk 
of complications and readmission [1]. 
Numerous studies have analyzed functional deterioration in patients after a 
hospital stay, especially in frail older people and immediately after discharge. 
Covinsky et al. [2] defined hospital-associated disability as the exacerbation of 
baseline disability following a hospital stay. The negative impact of hospitaliza-
tion has been studied from different perspectives and is associated with a high 
risk in both the development and the worsening of disabilities, especially in older 
people [3] [4]. Other authors have also described the appearance of unfavorable 
health events in up to 62% of patients between the first and third months 
post-discharge [5]. 
In PHS, 19.6% of patients require re-hospitalization within 30 days [6]. Al-
though researchers have tried to identify predictive factors for this outcome, 
there is still no completely validated model to promptly detect patients at greater 
risk [7]. Among the factors known to be associated with higher readmission 
rates in the early period, post-discharge is the failure to recover normal levels of 
serum albumin [8], low pre-admission autonomy in the basic activities of daily 
living, diminished autonomy during the hospital stay [9], certain comorbidities, 
and previous hospitalizations. Age is described as the main risk factor deter-
mining the deterioration from the baseline state, but its direct impact on read-
missions is not as clear. 
Certain factors related to the hospital stay itself can also favor the appearance 
of PHS. Many stressors are inherent to hospital admission: altered sleep habits, 
poor adaptation to a new environment, a large number of different professionals 
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involved in care, medication, pain, iatrogenic complications, forced immobility, 
and inadequate diet. Thus, a multifactorial perspective is required to study PHS 
in order to better predict the risk in each patient. 
Inpatients often present metabolic or hydroelectrolytic alterations, the most 
frequent of which is hyponatremia in the general as well as inpatient population, 
with an estimated in-hospital incidence of 1 per 100 patients per day and a pre-
valence of around 2.5% [10] [11]. However, this disorder is underdiagnosed and 
underreported, despite constituting an analytic alteration, so these data probably 
underestimate the real prevalence. 
There are many mechanisms involved in PHS affecting sympathetic activity, 
immune function, metabolism, coagulation, nutritional status, disturbance of sleep, 
physical functioning and coordination, pain and other discomforts. As a result, 
all those mechanisms may be associated during hospital stay with many different 
types of stressors (modify the circadian rhythm and sleep quality, multiple blood 
tests, constant alarm noises…). Additionally, the high complexity of the majority 
of patients attended in our Internal Medicine Service (multiple comorbidities) 
associated with the aging of the population (elderly and very elderly above 80 
years are the most vulnerable to the PHS) increase the occurrence of stressors, 
suggesting the possibility we have inadvertently been causing harm to these pa-
tients during hospitalization [12] [13].  
Hyponatremia is associated with greater in-hospital mortality, reaching up to 
20% in severe cases compared to less than 10% in patients who do not develop 
this disorder, and this risk remains high after discharge [14]. The condition also 
entails a higher risk of admission to the intensive care unit, a longer length of 
stay, and greater hospitalization costs [15]. The risk of readmission is also high 
in patients with hyponatremia [16], and can be related to some common condi-
tions (excessive hydration, chronic comorbidities decompensation, use of several 
medications and polypharmacy…), however, there is a need for more informa-
tion clarifying the link between this entity and PHS. 
The aim of this study is to assess the importance of hyponatremia in PHS in 
terms of one-month readmission rates following discharge from the internal 
medicine ward in patients with hyponatremia on admission, during the hospital 
stay, or at discharge. We hypothesized that hyponatremia would be associated 
with a high incidence of PHS. Secondary aims were to describe the characteris-
tics of patients with hyponatremia, the diagnostic process and clinical manage-
ment of the condition, and the mean interval from discharge to readmission 
and/or death. 
2. Material and Methods 
This descriptive, observational, longitudinal, retrospective study took place in 
the internal medicine ward of the University Hospital of San Juan (Alicante, 
Spain) and included all patients discharged from 1 September 2010 to 2 February 
2020 and whose discharge report included the diagnostic code for hyponatremia 
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(whether on admission, during the hospital stay, or at discharge). We excluded 
patients who died during their hospital stay or were transferred to another center 
or service. 
The Orion Clinic hospital database was used to identify patients meeting in-
clusion criteria during the study period, on request to the hospital’s clinical 
records department. Clinical histories were reviewed to collect demographic va-
riables; clinico-analytical parameters; and details on diagnosis and treatment at 
admission, during the hospital stay, at discharge and on readmission. Data were 
fully anonymized and confidential.  
For the descriptive statistical analysis, we calculated absolute and relative fre-
quencies for the categorical variables and the mean, standard deviation (SD), 
and range of the quantitative variables.  
3. Results 
A total of 25 patients were discharged from the internal medicine service during 
the study period, including 20 women (80%) and 5 men (20%). All were white, 
and their age ranged from 69 years to 95 years (mean 82.3 SD 7.7). 
Daily data on readmissions were collected for 30 days post-discharge in the 
included patients. Median length of stay was 4.1 days (SD 2.2, range 1-9). The 
most frequent comorbidities were hypertension (n = 22, 88%), dyslipidemia (n = 
12, 48%), and type 2 diabetes mellitus (n = 11, 44%) (Table 1). The etiology of 
the hyponatremia was unknown in nearly half the patients (n = 12, 48%); in the 
rest, the most common cause was pharmacological treatments (n = 7, 28%), 
which in three cases (12%) were diuretics. 
Pain, at any location, was the most frequent symptom on readmission (n = 12, 
48%), followed by dizziness and vomiting (n = 9, 36%) and nausea (n = 5, 20%). 
At discharge, the only symptom recorded was pain (n = 2, 8%). No differences in 
symptoms were observed when patients were split into two groups based on 
blood sodium levels (≥120 mmol/L versus <120 mmol/L). The principal diag-
noses were hypoosmolar hyponatremia (n = 4, 16%) along with moderate (n = 3, 
12%) and severe (n = 3, 12%) hyponatremia. 
The most commonly used treatments were angiotensin II receptor antagonists 
(ARA-II, n = 15, 60%), proton bomb inhibitors (PBI, n = 11, 44%), loop diuret-
ics (n = 10, 40%), and beta-blockers (n = 12, 48%). However, grouped by families, 
the antihypertensive drugs ARA-II along with angiotensin-converting-enzyme in-
hibitors (ACE inhibitors) were used in 20 patients (80%), and diuretics—whether 
alone or in combination, in 15 (60%). 
The parameters collected in this study are presented in Figure 1 and Table 2: 
[Na+]O and [K+]O were collected in 16 patients (64%); urine osmolality, thyroid 
stimulating hormone (THS), and free thyroxine (FT4), in 15 (60%); plasma os-
molality, in 14 (56%); plasma cortisol, in 7 (28%); and adrenocorticotropic hor-
mone (ACTH), in 2 (8%). 
Among the measures administered to correct the hyponatremia at discharge 
(Table 3), treatments were modified in 18 patients (72%). Medications that can 
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potentially cause hyponatremia were withdrawn in 16 patients (64%), especially 
ARA-IIs (n = 7) as well as the antidepressant selective serotonin reuptake inhi-
bitors (SSRI) and thiazides (n = 3 each), ACE inhibitors and anticonvulsants (n = 
2 each). Other modifications included water intake restrictions (n = 5, 20%) and  
 
Table 1. Comorbidities, etiology, and clinical, diagnostic, and treatment characteristics of 
included patients. 
Comorbidities n (%) Etiology n (%) 
Hypertension 22 (88) Unknown 12 (48) 
Diabetes 11 (44) SIADH  
Dyslipidemia 12 (48) Medication-induced 8 (32) 
Ischemic cardiopathy 2 (8) Idiopathic 2 (8) 
Heart failure 5 (20) Vomiting 1 (4) 
Kidney failure 7 (28) Multifactorial 2 (8) 
Acute COPD 1 (4)   
Signs and symptoms, n (%) Admission Hospitalization Discharge 
Pain 12 (48%) 3 (12%) 2 (8%) 
Nausea 5 (20%) 0 0 
Diarrhea 4 (16%) 0 0 
Agitation 2 (8%) 2 (8%) 0 
Dizziness 9 (36%) 0 0 
Confusion 4 (16%) 2 (8%) 0 
Falls 4 (16%) 0 0 
Diagnosis n (%) Treatment n (%) 
Hyponatremia  ARA-II 15 (60) 
Unknown origin 2 (8) ACE inhibitors 5 (20) 
Hypovolemic 1 (4) Beta-blockers 12 (48) 
Hypoosmolar 4 (16) Proton bomb inhibitor 11 (44) 
Mild 1 (4) Loop diuretics 10 (40) 
Moderate 3(12) Thiazides 6 (24) 
Severe 3 (12) SSRI 5 (20) 
Pharmacological hypotension 1 (4) Aldosterone antagonists 2 (8) 
Constitutional syndrome 2 (8) Anticonvulsants 4 (16) 
Ogilvie syndrome 1 (4)   
Fever 1 (4)   
SIADH 1 (4)   
Kidney failure 1 (4)   
Vomiting 1 (4)   
Respiratory failure 2 (8)   
ACE inhibitor: angiotensin-converting-enzyme inhibitor; ARA-II: angiotensin II receptor antagonists; 
COPD: chronic obstructive pulmonary disease; SIADH: syndrome of inappropriate antidiuretic hormone 
secretion; SSRI: selective serotonin reuptake inhibitors. 
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administration of urea (n = 2, 8%). Tolvaptan treatment was not used in any of 
the cases. 
Six patients were discharged with hyponatremia (mean blood sodium 132.5 
SD 1.6 mmol/L), which they had developed during their hospital stay. Five 
(20%) of these patients were readmitted within 30 days of discharge; five had  
 




Admission Hospitalization Discharge 
[Na+]P (mmol/L) 123.44 (6.51) 128.32 (5.55) 132.46 (6.98) 
[Na+]O (mmol/L) 49.44 (36.05) 61.17 (45.10) 65.14 (33.85) 
[K+]O (mmol/L) 46.22 (26.35) 25.50 (16.33) 21.68 (8.21) 
OsmP (mOsm/Kg) 264 (23.40) 267.25 (16.45) 274.11 (11.01) 
OsmO (mOsm/Kg) 440.83 (122.14) 354.29 (167.50) 328.85 (156.43) 
SD: standard deviation. 
 
Table 3. Routine treatment and treatment at discharge. 
Treatment Routine, n (%) At discharge, n (%) 
Loop diuretics 10 (40) 7 (28) 
Thiazides 6 (24) 3 (12) 
Aldosterone antagonists 2 (8) 1 (4) 
ACE inhibitors 5 (20) 3 (12) 
ARA-II 15 (60) 8 (32) 
Beta-blockers 12 (48) 12 (48) 
Proton bomb inhibitors 11 (44) 10 (40) 
Anticonvulsants 4 (16) 2 (8) 
SSRIs 5 (20) 2 (8) 
Water restrictions 0 (0) 5 (20) 
Urea 0 (0) 2 (8) 
Tolvaptan 0 (0) 0 (0) 
ACE inhibitor: angiotensin-converting-enzyme inhibitor; ARA-II: angiotensin II receptor antagonists; 
SSRI: selective serotonin reuptake inhibitors. 
 
 
Figure 1. Analytical parameters tested in the sample of patients with hyponatremia. 
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been advised to restrict water intake to 1 L/day, and two were given urea (15 
mg/12h). Mean blood sodium at readmission was 126.8 mmol/L (SD 3.4). The 
mean interval from discharge to readmission was 11.4 days (SD 5.1, range 5-19). 
Patients’ mean age was 77.6 years (SD 6.6), and heart failure was the cause of 
readmission in 2 of the patients (33%). All in all, five patients (20%) died during 
follow-up, including one within a month of discharge and four more in the fol-
lowing five months. 
4. Discussion 
This descriptive, observational, longitudinal and retrospective study involved 25 
patients with hyponatremia who had been discharged from the internal medi-
cine ward at our hospital. We wanted to determine whether hyponatremia was 
related to a higher rate of PHS, as assessed through the readmission rate in the 
first 30 days from discharge. 
The one-month readmission rate in our sample was 20%, a result in concor-
dance with the literature (19.6%). Our results suggest that hyponatremia may 
have an influence on PHS, independently of the rest of the comorbidities, carry-
ing a higher risk compared to readmission rates reported in normonatremia. 
The mean discharge-readmission interval, of 11.4 days, is consistent with the 
description of early vulnerability following hospitalization and highlights the 
importance of the transition from the hospital to home within the first month of 
discharge. 
Diuretics are one of the most frequent causes of hyponatremia [17] [18], espe-
cially thiazides (more than 60% of patients on these drugs present hyponatre-
mia) but also loop diuretics [19]. Hyponatremia is also associated with the use of 
SSRIs (about 32% of patients on SSRIs develop SIADH) and some antiepileptic 
drugs (40% SIADH). The results of our study are concordant with other pub-
lished research, and explain the measures adopted: diuretics and antidepressants 
were proportionally among the most frequently withdrawn drugs. 
Heart failure is responsible for up to 23% of the cases of hyponatremia, similar 
to our results (20%), despite our small sample size. Patients with heart failure 
have also been shown to carry an increased risk of readmission, as observed in 
our series, with a one-month readmission rate of 50%. Nevertheless, although 
some authors have proposed a causal relationship, other concomitant etiological 
factors should also be considered [20]. 
The cause of hyponatremia was unknown in nearly half of our patients (n = 
12, 48%), reflecting the scarce diagnostic attention and characterization of this 
entity. In our series, for example, SIADH was diagnosed in one patient (n = 1, 
4%) and noted as a possibility in one over the course of six months. The most 
frequent qualifier for hyponatremia was “hypoosmolar” (n = 4, 16%) with levels 
of OsmO of more than 100 mOsm/kg and [Na+]O of more than 30 mmol/L. All of 
these characteristics could indicate undiagnosed SIADH, which could have an 
impact on PHS due to hyponatremia and on treatment at discharge. 
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According to European guidelines [21], hyponatremia should be addressed 
first by measuring OsmP to rule out non-hypotonic hyponatremia. From there, 
the patient should undergo assessment for OsmO, [Na+]O and extracellular vo-
lume (ECV), which enables the classification of the hyponatremia as hypotonic 
with normal, elevated, or low ECV. This classification can orient the etiology. 
Clinically, it is important to assess the severity of the symptomology and the 
time since onset. SIADH is a diagnosis of exclusion, determined when a series of 
criteria are met, including the determination of [Na+]P, [Na+]O, [K+]O, OsmP, and 
OsmO as well as the exclusion of hypothyroidism and cortisol deficit. In the 
management of SIADH-induced euvolemic hyponatremia, it is necessary to 
measure the concentration of ions (Na and K) in urine) in order to calculate the 
Fürst index ([Na+]O + [K+]O)/[Na+]P), a prognostic indicator of the response to 
water restrictions and of the therapeutic response [22] [23]. In this study, we 
observed that the basic parameters for studying hyponatremia were scarcely stu-
died. Essential parameters were measured only in some patients, including Osmp 
(n = 14, 56%), Osmo (n = 15; 60%), and [Na+]O (n = 16, 64%). Only two patients 
underwent a complete study for euvolemic hypoosmolar hyponatremia even 
though this was the most commonly recorded type. The great variability among 
patients regarding the measurement of these parameters reflects the low impor-
tance given to this entity and the lack of a systematic approach in its manage-
ment. 
For managing hyponatremia attributed to a pharmacological origin, clinicians 
should suspend or change the medications responsible for causing the condition 
[24]. In our series, this was the most frequently applied measure (n = 16, 64%), 
mainly affecting thiazides, anticonvulsants, and SSRIs, and highlighting that the 
pharmacological etiology of hyponatremia is taken into account. The specific 
treatments for chronic hyponatremia attributed to SIADH, as the frequent cause 
among inpatients [25], mainly consisted of water restrictions and to a lesser ex-
tent urea. Tolvaptan was not used at all. European guidelines as well as recom-
mendations from international and Spanish experts agree that water intake re-
strictions should be the first-line treatment in non-severe cases. As an alternative 
or second-line intervention, European guidelines recommend the use of urea, 
especially in cases of SIADH. However, even though its use is accepted, the ben-
efits of urea have not been proven in any clinical trials. Moreover, it is not con-
sidered to be a medication, it has poor palatability, and it can provoke some 
complications, especially in older patients (dehydration, excessive correction). 
There is some controversy around the use of tolvaptan. The European guide-
line disadvises its use due to a low safety profile. In contrast, expert guidelines 
and other studies in the literature base their endorsement on published evidence 
of its efficacy and safety (SALT-1, SALT-2, and SALTWATER studies) [26] [27]. 
The algorithm of recommendations by experts in Spain also supports the use of 
tolvaptan. 
Thus, there is a lack of consensus and specificity around both the diagnosis 
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and therapeutic management of hyponatremia. This situation could generate some 
confusion or uncertainty in routine clinical practice, especially when deciding 
whether to administer a treatment appropriate for addressing SIADH of idiopath-
ic etiology. There is a need for further studies providing scientific evidence to 
inform the development of a systematic diagnostic and treatment approach for 
hypotonic hyponatremia. 
This study is the first that aims to associate hyponatremia due to any cause 
with PHS in a retrospective, real-world cohort. Our literature review revealed a 
dearth of adequate epidemiological studies, the scant clinical importance given 
to the entity, and its possible underdiagnosis. As a result, these patients may of-
ten be managed inappropriately and insufficiently, which could favor the devel-
opment of PHS and slow or complicate their recovery following hospitalization. 
Our study has some limitations. Its observational, retrospective nature, in a 
cohort of patients attended in a single ward by different professionals, may have 
influenced the variability in the diagnosis, therapeutic approach and treatment. 
Missing data in clinical records may have also affected the results or introduced 
bias. The small sample size is another limitation, which could be justified by the 
underreporting of hyponatremia. Strengths of the study include its focus on how 
hyponatremia is handled in routine clinical practice in our setting, highlighting 
the need to implement measures that improve its study in these patients and its 
impact on PHS. 
5. Conclusions 
Hyponatremia may be a cause of PHS, favoring the early readmission rate in dis-
charged patients. Larger studies are necessary to assess the relationship between 
PHS and hyponatremia and to demonstrate its clinical relevance. 
Hyponatremia is under-evaluated, underdiagnosed, and therefore undertreated. 
An adequate awareness and management of this entity are necessary to detect 
and correct it, enabling the medical community to reach a consensus and syste-
matize its assessment. Further, good-quality studies are needed to provide relia-
ble evidence. 
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PHS: Post-Hospital Syndrome; 
ARA-II: Angiotensin II Receptor Antagonists; 
ACE Inhibitors: Angiotensin-Converting-Enzyme Inhibitors; 
COPD: Chronic Obstructive Pulmonary Disease; 
SSRI: Selective Serotonin Reuptake Inhibitors; 
SIADH: Syndrome of Inappropriate Antidiuretic Hormone Secretion; 
[Na+]P/[Na+]O: Plamsa and Urine Sodium Concentration; 
[K+]O: Urine Potassium Concentration; 
OsmP:/OsmO: Plasma and Urine Osmolality. 
 
 
